BioLineRx (NASDAQ:BLRX) Now Covered by StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a report published on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright lowered their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Stock Down 3.6 %

Shares of BLRX stock opened at $0.11 on Monday. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. BioLineRx has a one year low of $0.08 and a one year high of $1.44. The company’s fifty day moving average price is $0.20 and its 200-day moving average price is $0.46. The company has a market capitalization of $8.43 million, a price-to-earnings ratio of -0.48 and a beta of 1.46.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. BioLineRx had a negative return on equity of 163.37% and a negative net margin of 90.57%. Sell-side analysts expect that BioLineRx will post -0.15 EPS for the current fiscal year.

Institutional Trading of BioLineRx

A hedge fund recently raised its stake in BioLineRx stock. Atria Investments Inc grew its position in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,974 shares of the biotechnology company’s stock after purchasing an additional 29,193 shares during the period. Atria Investments Inc owned approximately 0.17% of BioLineRx worth $72,000 at the end of the most recent reporting period. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.